Latest NS5 Stories
â€¢ Results add to data suggesting that SVR can be achieved with the combination of daclatasvir (BMS-790052) and asunaprevir (BMS-650032) in HCV genotype 1b patients â€¢ Study expanded to include
PRINCETON, N.J., July 6, 2011 /PRNewswire/ -- Pharmasset, Inc.
PRINCETON, N.J., June 22, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 ("the '580 patent") titled "Nucleoside Phosphoramidate Prodrugs".
PRINCETON, N.J., May 26, 2011 /PRNewswire/ -- Pharmasset, Inc.
ABBOTT PARK, Ill., May 18, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has received approval from the U.S.
BRISBANE, Calif., May 4, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Bank of America Merrill Lynch 2011 Health Care Conference in Las Vegas, NV on May 11, 2011, at 1:00 p.m.
Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment (SVR12).
- A trick or prank.